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ABSTRACT
Objectives Argentina is a low and middle- income country 
(LMIC) with a highly fragmented healthcare system that 
conflicts with access to healthcare stated by the country’s 
Universal Health Coverage plan. A tele- mammography 
network could improve access to breast cancer screening 
decreasing its mortality. This research aims to conduct 
an economic evaluation of the implementation of a tele- 
mammography program to improve access to healthcare.
Methods A cost- utility analysis was performed to explore 
the incremental benefit of annual tele- mammography 
screening for at- risk Argentinian women over 40 years 
old. A Markov model was developed to simulate annual 
mammography or tele- mammography screening in two 
hypothetical population- based cohorts of asymptomatic 
women. Parameter uncertainty was evaluated through 
deterministic and probabilistic sensitivity analysis. Model 
structure uncertainty was also explored to test the 
robustness of the results.
Results It was estimated that 31 out of 100 new cases 
of breast cancer would be detected by mammography 
and 39/100 by tele- mammography. The model returned 
an incremental cost- effectiveness ratio (ICER) of £26 
051/quality- adjusted life- year (QALY) which is lower 
than the WHO- recommended threshold of £26 288/QALY 
for Argentina. Deterministic sensitivity analysis showed 
the ICER is most sensitive to the uptake and sensitivity 
of the screening tests. Probabilistic sensitivity analysis 
showed tele- mammography is cost- effective in 59% of 
simulations.
Discussion Tele- mammography should be considered 
for adoption as it could improve access to expertise 
in underserved areas where adherence to screening 
protocols is poor. Disaggregated data by province is 
needed for a better- informed policy decision. Telemedicine 
could also be beneficial in ensuring the continuity of care 
when health systems are under stress like in the current 
COVID-19 pandemic.
Conclusion There is a 59% chance that tele- 
mammography is cost- effective compared to 
mammography for at- risk Argentinian women over 40- 
years old, and should be adopted to improve access to 
healthcare in underserved areas of the country.
INTRODUCTION
Breast cancer is the leading cause of death 
from cancer in women from all social strata. 
Seventy per cent of the global- reported 
deaths were in low and middle- income coun-
tries (LMIC).1
Population screening for breast cancer is 
strongly recommended by most guidelines, as 
it is highly curable if detected at early stages. 
The main goal is to allow diagnosis in asymp-
tomatic women. The Surveillance, Epidemi-
ology, and End Results programme of the 
US National Cancer Institute showed a good 
correlation of the stage at diagnosis with the 
5- year survival rates: 62.5% of women are diag-
nosed at stage I/II, accounting for a 5- year 
survival rate of 85.5%–98.8%, contrasting 
with those diagnosed at stage III/IV, where 
the 5- year survival rate falls up to 30%.2
The Argentinian National Cancer Institute 
ranks breast cancer as the most common 
cancer in the country with 19 000 cases diag-
nosed yearly. It represents 17% of all malig-
nancies with an incidence of 71 per 100 000 
and 32% of cancer in women.3 It is the leading 
cause of death from cancer in women, with 
an estimated mortality rate of 18.0 per 100 
000. According to the Pan American Health 
Summary
What is already known?
 ► Telemedicine has been shown to be cost- effective 
in improving access to health services in rural areas 
and for chronic conditions by improving monitoring 
of patients and adherence to treatments.
What does this paper add?
 ► With telemedicine having a crucial role in the 
screening and monitoring of chronic conditions 
during the COVID-19 pandemic, this would be the 
first paper that shows telemedicine—specifically 
telemammography—is cost- effective for breast 
cancer screening, and can guarantee the continuity 
of care and managing the surge caused by health 
emergencies like the current COVID-19 pandemic.
 ► It also opens up the possibility to explore the cost- 
effectiveness of telemammography in other national 
healthcare systems, particularly for other low and 
middle- income countries.
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Organization (PAHO), Argentina ranks the second 
region for breast cancer mortality.3
Argentina is a low to middle- income country where 
universal healthcare is guaranteed by the government. 
However, considerable inequalities in accessibility exist 
among different regions in the country, which challenge 
the adoption of mammography or ultrasonography 
for breast cancer screening and make it unaffordable 
for public and private healthcare providers in remote 
geographies.
Telemammography networks are an affordable and 
scalable way of improving treatment and prevention of 
breast cancer. They usually operate with a main centre 
and strategically located digital mammography facilities, 
particularly in remote or in- need areas. Women go to 
these facilities to have their mammography taken, then 
the images are sent to the main centre to be interpreted 
and sent back to the facility in less than 24 hours. This 
could reduce the access barriers to early diagnosis by, first, 
improving access to state- of- the- art technology like digital 
mammography; second, improving diagnostic accuracy 
by a remote interpretation by trained physicians; third, 
increasing the breast cancer awareness through involve-
ment of government bodies, civil societies and the private 
sector; and creating a pathway for national and regional 
cancer control programmes.
This research aims to conduct a cost- utility analysis of 
the implementation of a telemammography programme 
to provide a summary measure of efficiency that can later 




Argentinian guidelines recommend annual screening 
with mammography for all women between 40 and 74 
years old.5 Yet, access to the test is limited in rural areas 
where the uptake is as low as 39%.6
In this study, the current strategy was compared with 
a telemammographic approach. Both screening methods 
use the same machines (direct digital mammography and 
3D mammography for women with denser breast tissue) 
which met the technical standards of the European guide-
lines for quality assurance in breast cancer screening and 
diagnosis.7 The number of devices used was 1 for each 
group. Both tests have a high sensitivity to detect a subset 
of the population who should have confirmatory biopsy 
to determine the presence or absence of disease.8
Modelling strategy
A state- transition Markov model was developed on Micro-
soft Excel V.16.38 to inform a long- term decision model 
(figure 1). In this study, we simulated annual mammog-
raphy or telemammography screening methods for breast 
cancer in two hypothetical population- based cohorts of 
1000 asymptomatic Argentinian women over 40 years old 
who were assumed to be at risk of breast cancer but had 
not yet been diagnosed.
Natural history of disease
Figure 1 illustrates the natural history of the disease used in 
this evaluation, and was adapted from a published study.9 
In each cycle, women could either remain cancer free, 
die from all- cause death or progress into stage I. From 
here, women could either subsequently transition into 
stages II, III, IV and cancer- related death or go directly 
into more severe stages (eg, I to III or I to IV directly). 
From each stage, women could die from other causes or 
cancer- related causes. Stage I cases detected by either 
screening test were treated accordingly if confirmed. The 
false negatives or missed cases by both tests that later on 
developed the disease were assumed to debut as ‘new 
cases’ progressing from healthy directly to stage II, III or 
IV.
Epidemiological and clinical data
The invasive breast cancer incidence standardised by age 
was combined from four different provinces in Argen-
tina: Bahia Blanca, Córdoba, Mendoza and Tierra del 
Fuego.10–12 The stage distribution data with telemammog-
raphy were provided directly by a private telemammog-
raphy firm in Argentina to improve the comparability 
of the results. These data are not publicly available. 
Figure 1 State- transition Markov model for breast cancer progression adapted for this study population, with transition 
probabilities.
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Non- detected breast cancer cases in stage I are assumed 
to be included as ‘new cases’ that appeared directly in 
later stages II, III and IV, which would add to the ones 
transitioned from previous stages.
Characteristics of the tests
For this model, a baseline sensitivity of 78% (95% CI 
75% to 90%) was used for both comparators, with a 
specificity of 64.5%, a positive predictive value of 89% 
and a diagnostic accuracy of 89.3%.13 14 To validate that 
the same sensitivity could be used, we based our case 
in a study comparing 26 radiology services in Argen-
tina, Bolivia, Colombia, Cuba and Mexico, funded by 
the PAHO.15 Argentina has shown the highest quality 
measures of all the participating countries as it had 
the greatest number of doctors working full time on 
breast cancer diagnosis and the quality of the image 
and certainty of radiological interpretation was the 
highest of the region.15
Quality-adjusted life-years gained
Argentina adheres to the MERCOSUR economic 
evaluation guidelines which recommend quality- 
adjusted life- year (QALY) as the best measure of 
health outcomes in cost- effectiveness analyses.4 The 
calculation formula used for this study was ‘Years of 
Life’ × ‘Utility Value’=number of QALYs. Utility scores 
used were taken from published literature.16 The 
state of death had a value of zero and no disutility for 
screening or false- positive results were considered.
Costs
Resource use was calculated from a societal perspec-
tive to account for the underlying concept of oppor-
tunity cost.17 To account for currency issues, the real 
conversion factor from the National Bank was used for 
costs in Argentine pesos (ARS). For non- ARS costs, the 
World Bank’s purchasing power parity (PPP) index 
was used. Adjustment for inflation was done using the 
gross domestic product (GDP) deflator index as all 
costs were updated to 2020 figures.18 Future costs and 
future benefits were discounted at 3%.4
Direct screening costs
The direct screening costs were divided into two main 
categories: medical and non- medical. The medical 
costs include: the cost of the screening tests and, in 
the case of mammography, an additional medical 
appointment with a mastologist.19 The price used for 
mammography screening (£47.85/test) was calcu-
lated as an average of the public (£24.23/test) and 
private (£71.47/test) sector costs, while the price for 
telemammography screening was reported directly by 
two private clinics in Argentina, including the human 
resources cost (£8.72/test).
A ‘set- up cost’ of an additional £0.38/test was consid-
ered for the telemammography group calculated by 
dividing the new centre’s yearly ‘maintenance fee’ of 
£2250/year by the average number of tests per centre.
Non- medical screening costs measured were mainly 
transportation to the centre and cost of a family caretaker 
for the test day.20 21
Direct treatment costs
Direct medical costs associated to cancer treatment 
include surgery, chemotherapy, radiotherapy and 
‘other procedures’ including medical visits and treat-
ment for adverse events and were valued for each 
cancer stage. The costs for Argentina were derived 
from published studies in Mexico, Colombia and 
Brazil; weighted by the sample size of the study, 
accounted for inflation and currency conversion. So 
for this study, the average standard lifetime treatment 
costs resulted in £21 482, £32 683, £38 406 and £44 
508 for stages I, II, III and IV, respectively. All param-
eters used for the base case as well as their public 
sources are displayed in table 1.
Base case analysis
The model followed a cohort of 1000 at- risk 40- year- old 
Argentinian women over a lifetime horizon. The 
economic evaluation output was the incremental 
cost- effectiveness ratio (ICER), and cost per life- year 
gained was also reported. A threshold of three times 
the GDP of Argentina was used to decide on whether 
telemammography was cost- effective compared with 
mammography, following a general recommendation 
of the WHO guidelines.17 According to the World 
Bank in 2018, the GDP per capita in Argentina was (in 
US$) $11 633, which when converted to British pound 
sterling using the PPP index is £8762.6; therefore, in 
this study, a cost- effectiveness threshold of £26 288/
QALY was used.18
Uncertainty and sensitivity analysis
Deterministic and probabilistic sensitivity analysis
We carried out one- way and probabilistic sensitivity anal-
yses (PSA) to explore parameter uncertainty. In the deter-
ministic sensitivity analysis (DSA), we varied the uptake 
and sensitivity of the tests, discount rate of future costs 
and outcomes and the quality of life (QoL) within their 
minimum and maximum scores. The costs included on 
this DSA were varied by an increase/decrease of 30%. 
This model was based on a series of structural assump-
tions, one being all ‘missed cases’ undetected in stage I 
were lost and not identified in stages II, III and IV; tested 
by DSA.
PSA was conducted to assess the uncertainty of all 
relevant parameters simultaneously. Costs followed a 
gamma distribution whereas QoL, the uptake rates and 
the sensitivity of the tests followed a beta distribution as 
suggested in the literature. All the input variables were 
varied simultaneously, and we could obtain 1000 esti-
mates of incremental costs and effects by sampling from 
the distribution summarised in two measures of param-
eter uncertainty: the incremental net monetary benefit 
and the cost- effectiveness acceptability curves (CEACs). 
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Table 1 Summary of input variables used for the base model analysis
Variable description Source
Sample size 1000 –
Discount factor for costs and outcomes 3% (95% CI 2% to 6%) WHO guidelines17
Age- specific probabilities
Age band Incidence of breast cancer All- cause mortality   
  40–44 0.001220 0.00168
CI5 Vol X*
National Institute of Statistics and Census (INDEC), Argentina10 11
  45–49 0.002019 0.00266
  50–54 0.002271 0.00412
  55–59 0.003085 0.00629
  60–64 0.003142 0.00930
  65–69 0.003135 0.01410
  70–74 0.003223 0.02228
  75–79 0.002971 0.03812
  80–84 0.003095 0.07289
  85+ 0.003204 0.23 153
Stage distribution of breast cancer
Population Mammography Telemammography   
Stage I 0.244 0.132 0.428
MoH official figures (Argentina)
Published ‘Dr. Jose Ramon Vidal’ Hospital Data (Corrientes, 
Argentina)12
Stage II 0.449 0.283 0.326
Stage III 0.231 0.299 0.167
Stage IV 0.043 0.278 0.080
Disease progression- transition probabilities
Stage I Stage II Stage III Stage IV Cancer 
death
  
Stage I 0.4 0.29 0.09 0.13 0.09 Mexican Social Security Institute (case study)30
Stage II – 0.55 0.22 0.18 0.05
Stage III – – 0.22 0.7 0.09
Stage IV – – – 0.14 0.86
Characteristics of the tests
Mammography Telemammography (TM)   
Specificity 0.865 (95% CI 0.83 to 0.90)
MoH official figures (Argentina)6
Private (TM centre)
Sensitivity 0.78 (95% CI 0.75 to 0.90)
Uptake 0.39 (95% CI 0.32 to 0.46) 0.5 (95% CI 0.43 to 0.57)
Utility scores
Point estimate 95% CI   
Stage I 0.91 0.314 to 1.00 Pataky et al16
Stage II 0.75 0.320 to 0.983
Stage III 0.51 0.272 to 0.745
Stage IV 0.45 0.203 to 0.557
COSTS
Variable description Cost in ARS Year Cost in GBP Source
Direct screening costs
Direct medical costs
  Mammography (public sector) $2279 2020 £ 24.23 Official figures (Argentina)19
  Medical consults (specialist) $470 2020 £ 5
  Mammography (private sector) $6721 2020 £ 71.47 Private data
  Telemammography $810 2020 £ 8.72
  Mammography—average $4500 2020 £ 47.85 Calculation
Set- up costs (telemammography)
Continued
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The CEAC was plotted to show the probability of the 
intervention being cost- effective at different willingness- 
to- pay (WTP) thresholds.
RESULTS
Our model predicted 100 new cases of breast cancer for 
every 1000 women over a lifetime, of which 31 cases were 
detected by mammography and 39 by telemammography, 
and the rest missed. The estimated lifetime cost was £35 
875 for a woman in the mammography cohort gaining an 
average of 22.61 life- years per annum of which 22.38 were 
QALYs. For the telemammography group, the lifetime 
cost was £37 545, gaining 22.68 life- years of which 22.45 
were QALYs. The base case returned an ICER of £26 051 
and a cost of £21 391 per life- year gained, which are both 
slightly lower than the WHO- recommended threshold of 
£26 288/QALY for Argentina. Data are shown in table 2.
Deterministic sensitivity analysis
As expected, the ICER proved very sensitive to the uptake 
of mammography (£30 937–£459), telemammography 
(£6644–£29 887) and the QoL in stage I where a decrease 
to the lower end of the CI would increase the ICER to £46 
752. The ICER was also very responsive to the sensitivity of 
the tests; when it increased to 90% the ICER plummeted 
to £13 702. Other parameters that unilaterally impacted 
the ICER considerably were an increased discount rate 
of 6%, the QoL in stage II and the direct medical costs 
of mammography varying the ICER±8% both ways. 
For model structure robustness, we tested the extreme 
scenario that all cancer cases not detected in stage I were 
Table 2 Summary of base case analysis
Comparators Discounted years Discounted QALY Discounted costs
Mammography 22.6066 22.3846 £ 35 874.82
Telemammography 22.6847 22.4487 £ 37 545.19






  0.0781 0.0641 £ 1 670.36
ICER £ 26 051.32
Costs/LYG £ 21 390.76
ICER, incremental cost- effectiveness ratio; LYG, life- year gained; QALY, quality- adjusted life- year.
COSTS
Variable description Cost in ARS Year Cost in GBP Source
  Online campaigns 2019 £ 10 073.08 Private data
  Offline campaigns 2019 £ 9 258.21
  Opening a new clinic 2019 £ 73 500.00
  Number of tests per clinic (year) 2019 6000
  Additional screening cost/test 2019 £ 16.58 Calculation
  Leasing model (8- year contract) 2020 £ 2 250 Private data
  Additional screening cost/test 2020 £ 0.38 Calculation
Direct non- medical costs
  Distance to mammography centre 2020 200 km Private data
  Distance to telemammography centre 2020 50 km
  Price for transport/km 2019 £ 0.17 Official figures (Argentina)20 21
  Average daily cost of informal care (caretaker) 2019 £ 11.31
  Total non- medical costs of mammography 2020 £ 39.39 Calculation
  Total non- medical costs of telemammography 2020 £ 10.83 Calculation
Direct treatment costs
  Stage I 2018 £ 21 482.39 Average treatment costs: Brazil, Colombia 
and Mexico30
  Stage II 2018 £ 32 683.87
  Stage III 2018 £ 38 406.00
  Stage IV 2018 £ 44 508.32
*Cancer Incidence in Five Continents (CI5) Vol X report by the International Agency for Research on Cancer (IARC).
ARS, Argentine peso; GBP, British pound sterling; MoH, Ministry of Health.
Table 1 Continued
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lost and did not vary the ICER considerably. The tornado 
diagram in figure 2 shows the results of the DSA.
Probabilistic sensitivity analysis
The cost- effectiveness plane in figure 3 shows the ICER 
result of 1000 simulations in the PSA. The majority of the 
dotted cloud fell in the—north and south—eastern quad-
rants, meaning that most of the simulations resulted in a 
greater increase in QALY.
The CEAC presented in figure 4 showed that at the 
WHO- recommended threshold for Argentina of £26 
288/QALY, there is a 59% chance of telemammography 
being cost- effective.
DISCUSSION
The main findings of this societal cost- utility analysis indi-
cate that with a total medical and non- medical screening 
cost of £19.92, annual telemammography leads more 
QALY per additional costs than annual mammography 
for breast cancer screening in at- risk Argentinian women 
over 40 years old.
This study provides the first evidence that, from a 
societal perspective, telemammography is cost- effective 
compared with mammography screening in an LMIC 
and it could be a way to improve access to health services 
in remote areas. With telemedicine having a crucial role 
in the screening and monitoring of chronic conditions 
during the COVID-19 pandemic, this would be the first 
paper that shows telemedicine is cost- effective for breast 
cancer screening.
The results of this study are aligned with published liter-
ature looking at cost- effectiveness of general telemedicine. 
A systematic review of 21 economic evaluations concluded 
that telemedicine was cost- effective in most medical fields 
for diagnosis and management of chronic conditions, but 
not for acute care.22 As in this study, the literature concludes 
that the cost- effectiveness of telemedicine is related to three 
major factors: cost sharing (patient volume and lowering 
infrastructure costs); effectiveness of telemedicine in terms 
of patient utility and successful clinical consultations; and 
indirect societal cost savings by decreasing cost of patients’ 
lost productivity.23 Advancements in automation technol-
ogies like artificial intelligence and machine learning are 
allowing tasks such as diagnosing through imaging to be 
done more cost- efficiently and potentially more accurately, 
but more research is required to accurately gauge the 
extent of these benefits and understand the risks of reli-
ance on these technologies.
Barriers to implementing a breast cancer screening 
programme
Despite rarely incurring direct out- of- pocket expenses at 
the point of care, Argentina sees a very low level of uptake 
Figure 2 Tornado diagram—deterministic sensitivity 
analysis (one way). The incremental cost- effectiveness ratio 
(ICER) proved very sensitive to the uptake of mammography 
(£30 937–£459), telemammography (£6 644–£29 887) and 
the QoL in stage I where a decrease to the lower end of 
the CI would increase the ICER to £46 752. The ICER was 
also very responsive to the sensitivity of the tests; when it 
increased to 90% the ICER plummeted to £13 702.table 1 M, 
mammography; QoL, quality of life; TM, telemammography.
Figure 3 Cost- effectiveness plane—probabilistic sensitivity 
analysis results. The cost- effectiveness plane shows the 
incremental cost- effectiveness ratio (ICER) result of 1000 
simulations in the probabilistic sensitivity analysis. The 
majority of the dotted cloud fell in the—north and south—
eastern quadrants, meaning that most of the simulations 
resulted in a greater increase in quality- adjusted life- year 
(QALY). table 1 GDP, gross domestic product.
Figure 4 Cost- effectiveness acceptability curve—
probabilistic sensitivity analysis (PSA) results. The cost- 
effectiveness acceptability curve shows that at the 
WHO- recommended threshold for Argentina of £26 288/
quality- adjusted life- year (QALY), there is a 59% chance 
of telemammography being cost- effective.table 1 ICER, 
incremental cost- effectiveness ratio.
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of breast cancer screening due to various personal and 
cultural barriers. Telemammography has the potential to 
improve access to expert diagnoses by overcoming these 
barriers by combining elements, including reduced travel 
times and improved education regarding the procedure.
These barriers must be explored to understand why 
national- level screening programmes are failing in 
some countries. A literature review including 35 articles 
concerning beliefs and attitudes towards breast cancer 
screening in Latin America concluded that, apart from 
resources and personnel, ‘competent community educa-
tional interventions across all aspects of breast cancer’ 
are vital to ensure a successful population screening 
programme.24 In some LMICs, the lack of breast cancer 
awareness could cause a 29- month delay on average in 
medical care after self- detecting a breast lump, which 
resulted in diagnoses at more advanced stages.25 There-
fore, a screening programme with a strong educational 
component is key to ensure high participation rates in 
Argentina.
Other deterrents of care- seeking behaviour included: 
fear of disease, pain and embarrassment of the exam-
ination, self- neglect (from Spanish adjective ‘flojera’), 
fatalism about testing positive, lack of family and social 
support (taboo), language barriers and geographical 
barriers (transportation); the last one being vital in such 
a large country as Argentina. Perception of the staff’s 
clinical experiences also proved to be a barrier for test 
acceptance.24
These unmet needs are magnified by the current 
COVID-19 pandemic where cancer diagnostics and 
surgery have been disrupted by the response to the 
pandemic with reduction in survival rates of 13% (stage 
II) and 18% (stage III) as a consequence.26 Telemammog-
raphy, usually having smaller, less crowded centres sepa-
rated from hospitals, can be a way of reducing exposure 
to the virus while continuing screening. More research 
needs to be done, but a telemedicine model of health-
care delivery may offer systemic cost reduction through 
reduced levels of infection for patients and health 
professionals.
Limitations of the study and difference with other studies
Data and model structure
Data were imported from other studies that may not be 
representative or generalisable to the Argentinian popu-
lation. Nevertheless, careful consideration was put into 
using data from comparable countries (middle income 
or Latin America where possible) and updating the costs 
accordingly. An analysis stratified by province could 
improve accuracy, but no regional- level data were avail-
able, and is also out of the scope of this research. Addi-
tionally, no disutility for screening or false- positive results 
were considered.
Critique of the threshold
There is little theoretical justification regarding 
setting such a hard rule as the threshold is not linked 
to the country’s affordability, budget impact, feasi-
bility of implementation or the cost compared with 
other necessary and feasible interventions.27 Also, 
hard thresholds do not consider ethical implica-
tions, judgements of social value or equity issues. Not 
contemplating respects of local settings jeopardises 
generalisability to all decision- making contexts as 
countries are interested in other macro aspects, and 
not in efficiency alone.
Comparators
Having a no- screening arm could be more represen-
tative of the screening reality of most regions where 
this programme is being considered, as uptake of 
mammography is less than 50%. The negative impact 
of overdiagnosis must be considered for the addi-
tional cost to the health system in confirmatory testing 
and follow- ups, and because it negatively impacts the 
QoL of those patients. Furthermore, effectiveness of 
a screening programme is challenging to measure 
because of selection bias (higher risk perception of 
those being screened), lead time bias (longer ‘survival’ 
time observed due to an earlier date of diagnosis) and 
length time bias.28 More research could include other 
comparators like targeted risk screening, ultrasound or 
adjuvant endocrine therapy.
Difference with other studies
Some studies concluded that in addition to acute condi-
tions, telemedicine was not cost- effective for airway 
cancer.22 23 Several reasons can explain this difference 
in results. First, that telemedicine is very sensitive to 
the volume of patients treated, and incidence of breast 
cancer in Argentina is five times the incidence of lung 
and airway cancer in Scotland.29 Also, there is generally 
more education and public awareness of the need to 
screen for breast cancer than to diagnose lung cancer 
cases. Finally, the cost for telemammography infrastruc-
ture follows economies of scale logic being easier to 
reduce via, for example, leasing options than infrastruc-
ture costs for tele- endoscopy.
CONCLUSIONS
Our findings show that the ICER fell within the WTP 
threshold currently recommended by the WHO nearly 
60% of the time. This means that there is almost a 60% 
chance that telemammography is actually cost- effective 
compared with mammography for at- risk Argentinian 
women over 40 years old, and should be adopted as a 
population- based screening methodology for breast 
cancer, especially to improve access to the very poor, 
underserved areas of the country. However, because of 
generalisability, affordability and ethical implications, 
further research is vital to guide making a more benefi-
cial policy decision.
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Research in context
Significance of the study
This study provides the first evidence that, from a societal 
perspective, telemammography is cost effective compared 
to mammography screening in a Low- and Middle- Income 
Countryand it could be a way to improve access to health 
services in remote areas.
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